Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for perioperative anxiety, depression, and postoperative pain
ChiCTR2100053641Phase 4Recruiting
- Sponsor
- Shuhaihua
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in anxiety disorder, major depressive disorder (MDD) and Persistent postsurgical pain (PPSP) (2 arms), sponsored by Shuhaihua. Primary endpoint: Decrease in anxiety and depression score. Started Aug 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
anxiety disordermajor depressive disorder (MDD)Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on ChiCTR2100053641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053641.